Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
In this study, participants with Type 1 diabetes received insulin through an infusion into a
vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for
injection under the skin, and their blood glucose was measured for 3 hours.
The main objective of this study was to evaluate the safety and efficacy of intranasal and
subcutaneous glucagon (SC) in reversing insulin-induced hypoglycemia in participants with
type 1 diabetes.